Dishman Carbogen Amcis Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Dishman Carbogen Amcis Share Price

178.99-1.25 (-0.70%)

Pre Open
As On: 16 Jun, 2026, 09:02 AM IST
As On: 16 Jun, 2026, 09:00 AM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	181.40
High	-
Low	-
Prev Close	180.24
Volume	553
VWAP(₹)	-

Key Metrics

PE Ratio(x)	29.00
EPS - TTM(₹)	6.22
MCap(₹ Cr.)	2,825.86
MCap Rank	75
PB Ratio(x)	0.42
Div Yield(%)	-
Face Value(₹)	2.00
52W High(₹)	321.95
52W Low(₹)	128.50
MCap/Sales	0.70
Beta(1 Month)	1.07
BV/Share(₹)	425.87

Dishman Carbogen share price insights

Employee & Interest Expense
Company has spent 5.94% of its operating revenues towards interest expenses and 49.35% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)
Dishman Carbogen Share Price Update
Dishman Carbogen Amcis Ltd. share price moved down by -0.70% from its previous close of Rs 180.24. Dishman Carbogen Amcis Ltd. stock last traded price is 178.99
Share Price Value
Today/Current/Last 178.99185.00
Previous Day 180.24180.05

Found Insights useful?

Dishman Carbogen Share Price Returns

1 Day	-0.7%
1 Month	-7.86%
3 Months	8.26%
1 Year	-34.75%
3 Years	42.28%
5 Years	-12.13%

Dishman Carbogen Share Recommendations

Recent Recos

Target₹230
OrganizationYes Securities
BUY

Target₹380
OrganizationHDFC Securities
BUY

Target₹355
OrganizationHDFC Securities
BUY

View all Stock Recommendations

News & Analysis

View all Dishman Carbogen Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	867.82	726.46	660.76	732.80	724.31
Total Income Growth (%)	19.46	9.94	-9.83	1.17	5.28
Total Expenses	778.39	691.11	587.89	651.37	654.49
Total Expenses Growth (%)	12.63	17.56	-9.75	-0.48	6.92
EBIT	89.43	35.35	72.87	81.43	69.82
EBIT Growth (%)	152.98	-51.49	-10.51	16.63	-7.93
Profit after Tax (PAT)	21.74	-12.97	65.27	23.41	43.09
PAT Growth (%)	-	-119.87	178.81	-45.67	830.67
EBIT Margin (%)	10.31	4.87	11.03	11.11	9.64
Net Profit Margin (%)	2.51	-1.79	9.88	3.19	5.95
Basic EPS (₹)	1.39	-0.83	4.16	1.49	2.75

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	97.55	46.78	71.47	100.28	111.57
Total Income Growth (%)	108.53	-34.55	-28.73	-10.12	25.32
Total Expenses	82.89	58.34	71.68	75.90	101.67
Total Expenses Growth (%)	42.08	-18.61	-5.56	-25.35	12.27
EBIT	14.66	-11.56	-0.21	24.38	9.90
EBIT Growth (%)	-	-	-100.86	146.26	-
Profit after Tax (PAT)	-4.34	-23.13	-13.60	2.67	-7.37
PAT Growth (%)	-	-	-609.36	-	-
EBIT Margin (%)	15.03	-24.71	-0.29	24.31	8.87
Net Profit Margin (%)	-4.45	-49.44	-19.03	2.66	-6.61
Basic EPS (₹)	-0.28	-1.47	-0.87	0.17	-0.47

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	2,987.84	2,733.18	2,643.98	2,440.69	2,184.11
Total Revenue Growth (%)	9.32	3.37	8.33	11.75	11.98
Total Expenses	2,879.14	2,695.76	2,760.10	2,447.13	2,173.72
Total Expenses Growth (%)	6.80	-2.33	12.79	12.58	9.06
Profit after Tax (PAT)	97.45	3.24	-153.45	-29.80	18.01
PAT Growth (%)	2,907.72	-	-	-265.46	-
Operating Profit Margin (%)	9.64	7.26	0.14	3.28	3.13
Net Profit Margin (%)	3.32	0.11	-5.86	-1.23	0.84
Basic EPS (₹)	6.22	0.21	-9.79	-1.90	1.15

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	316.08	432.82	390.40	454.71	368.50
Total Revenue Growth (%)	-26.97	10.87	-14.14	23.39	38.29
Total Expenses	375.33	463.65	490.35	548.91	445.90
Total Expenses Growth (%)	-19.05	-5.45	-10.67	23.10	4.06
Profit after Tax (PAT)	-38.40	-9.87	-76.41	-58.87	-31.55
PAT Growth (%)	-	-	-	-	-
Operating Profit Margin (%)	11.77	9.89	-9.70	-9.01	-13.26
Net Profit Margin (%)	-16.58	-2.46	-23.34	-14.62	-10.41
Basic EPS (₹)	-2.45	-0.63	-4.87	-3.75	-2.01

All figures in Rs Cr, unless mentioned otherwise

Insights

Employee & Interest Expense
Company has spent 5.94% of its operating revenues towards interest expenses and 49.35% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	11,923.31	9,999.15	9,581.41	9,453.50	8,637.45
Total Assets Growth (%)	19.24	4.36	1.35	9.45	3.76
Total Liabilities	5,246.41	4,167.63	3,953.91	3,643.83	3,088.51
Total Liabilities Growth (%)	25.88	5.41	8.51	17.98	17.62
Total Equity	6,676.90	5,831.52	5,627.50	5,809.67	5,548.94
Total Equity Growth (%)	14.50	3.63	-3.14	4.70	-2.63
Current Ratio (x)	1.23	1.14	0.75	1.07	1.30
Total Debt to Equity (x)	0.42	0.36	0.35	0.31	0.26
Contingent Liabilities	0.00	492.23	621.71	675.78	758.07

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	5,126.04	5,122.35	5,076.66	5,181.04	5,214.31
Total Assets Growth (%)	0.07	0.90	-2.01	-0.64	-6.08
Total Liabilities	1,243.81	1,091.87	1,024.08	1,066.73	982.53
Total Liabilities Growth (%)	13.92	6.62	-4.00	8.57	12.02
Total Equity	3,882.23	4,030.48	4,052.58	4,114.31	4,231.78
Total Equity Growth (%)	-3.68	-0.55	-1.50	-2.78	-9.47
Current Ratio (x)	0.79	1.04	0.95	1.01	1.39
Total Debt to Equity (x)	0.16	0.17	0.13	0.14	0.12
Contingent Liabilities	0.00	519.06	580.56	642.28	625.19

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	491.45	375.23	383.97	220.34	354.85
Net Cash used in Investing Activities	-245.34	-192.21	-229.52	-448.46	-618.53
Net Cash flow from Financing Activities	200.58	-102.09	-22.15	249.67	130.37
Net Cash Flow	446.69	76.98	132.30	21.55	-133.31
Closing Cash & Cash Equivalent	787.76	341.07	264.09	131.79	110.24
Closing Cash & Cash Equivalent Growth (%)	130.97	29.15	100.39	19.55	-54.73
Total Debt/ CFO (x)	5.65	5.55	5.12	8.28	4.00

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	46.11	55.81	24.17	-52.90	227.35
Net Cash used in Investing Activities	21.68	-79.64	96.57	40.71	-172.67
Net Cash flow from Financing Activities	-119.59	87.51	-130.76	1.38	-46.16
Net Cash Flow	-51.80	63.68	-10.02	-10.81	8.52
Closing Cash & Cash Equivalent	15.93	67.73	4.05	14.07	24.88
Closing Cash & Cash Equivalent Growth (%)	-76.48	1,572.35	-71.22	-43.45	52.08
Total Debt/ CFO (x)	13.68	12.16	21.68	-11.15	2.32

All figures in Rs Cr, unless mentioned otherwise

Insights

Increase in Cash from Investing
Company has used Rs 245.34 cr for investing activities which is an YoY increase of 27.64%. (Source: Consolidated Financials)

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	1.45	0.05	-2.72	-0.51	0.32
Return on Capital Employed (%)	2.94	2.43	0.05	1.03	0.93
Return on Assets (%)	0.81	0.03	-1.60	-0.31	0.20
Interest Coverage Ratio (x)	3.57	3.08	2.62	4.20	6.60
Asset Turnover Ratio (x)	0.27	0.28	0.27	0.27	0.04
Price to Earnings (x)	20.92	1,111.11	-24.10	-65.79	161.29
Price to Book (x)	0.31	0.59	0.66	0.34	0.52
EV/EBITDA (x)	6.15	10.17	16.67	9.97	11.08
EBITDA Margin (%)	21.20	18.09	12.03	14.91	17.50

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	-0.98	-0.24	-1.88	-1.43	-0.74
Return on Capital Employed (%)	0.64	0.88	-0.71	-0.79	-0.86
Return on Assets (%)	-0.74	-0.19	-1.50	-1.13	-0.60
Interest Coverage Ratio (x)	1.04	1.49	1.02	1.03	2.68
Asset Turnover Ratio (x)	0.05	0.08	0.06	0.08	0.06
Price to Earnings (x)	-53.19	-357.14	-48.54	-33.22	-92.59
Price to Book (x)	0.53	0.85	0.91	0.48	0.69
EV/EBITDA (x)	29.29	38.21	60.25	41.33	33.47
EBITDA Margin (%)	38.79	26.20	21.33	14.88	32.99

Found Financials useful?

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
41%
Positive Movement
since 1st Jan 2005
on basis
57%
Negative Movement
since 1st Jan 2005
on basis
Exclude
Global Meltdown1st Jan 2008 to 10th Nov 2008
Covid Crisis1st Feb 2020 to 31st Mar 2020
Pivot Levels
R1 - Pivot
-
S1 -
R2 - S2 -
R3 - S3 -
Average True Range
5 Days 14 Days 28 Days
- - -

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Dishman Carbogen	29.00	0.42	1.45	2.94	0.81	6.90	9.64	3.32	6.22	1.23	0.42	5.65
Sequent Scientific	91.30	3.51	6.08	12.55	3.83	33.99	13.52	6.56	4.09	2.38	0.15	1.35
Sun Pharma Adv Res.	4.79	5.55	116.01	112.89	71.54	95.04	85.11	82.65	47.86	2.47	0.42	-2.33
Innova Captab	38.50	4.97	12.91	15.27	7.66	20.29	12.58	8.64	24.63	1.87	0.31	2.94
Orchid Pharma	239.43	3.78	1.59	2.50	1.07	7.22	5.03	2.61	4.05	2.45	0.28	3.53
Add More

Annual Ratios (%)

Choose from Peers

Zota Healthcare
Gujarat Themis
RPG Life Sci
Gufic BioSci
Aarti Drugs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 9,30,07,442 59.32 % 0.00
Pledge 0 0.00 % 0.00
FII 1,16,77,291 7.44 % -0.21
DII 25,42,995 1.62 % 0.36
MF 16,59,515 1.06 % -0.02
Others 4,95,55,367 31.61 % -0.14
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 59.32 59.32 59.32 59.32
Pledge 0.00 0.00 0.00 0.00
FII 7.44 7.66 8.07 9.94
DII 1.62 1.26 1.36 1.26
Mutual Funds 1.06 1.08 1.08 1.07
Others 31.61 31.75 31.25 29.47

Mutual Funds Ownership

MF Ownership as on 31 May 2026

HSBC Flexi Cap Direct-G
Equity: Flexi Cap
4
- 43.13
  Amount Invested (in Cr.)
- 0.78%
  % of AUM
- 19.11
  % Change (MoM basis)
Motilal Oswal BSE Healthcare ETF-G
Equity: Sectoral-Pharma
- 0.03
  Amount Invested (in Cr.)
- 0.08%
  % of AUM
- -9.50
  % Change (MoM basis)
Bandhan BSE Healthcare Index Direct-G
Equity: Sectoral-Pharma
- 0.02
  Amount Invested (in Cr.)
- 0.09%
  % of AUM
- 6.76
  % Change (MoM basis)

View all Mutual Fund Schemes

Dishman Carbogen Top Searches

Corporate Actions

Recent
General Meeting
-
May 26, 2026
Board Meeting
Audited Results
May 14, 2026
Board Meeting
To consider Fund Raising
Mar 16, 2026

Announced on	Meeting on
May 14, 2026	May 19, 2026
Audited Results
Mar 16, 2026	Mar 18, 2026
To consider Fund Raising
Jan 29, 2026	Feb 03, 2026
Quarterly Results
Dec 23, 2025	Dec 27, 2025
To consider Fund Raising
Oct 30, 2025	Nov 04, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
May 15, 2019 Sep 12, 2019 10%
Bonus
No Data Available
Splits
No Data Available
Rights
No Data Available
AGM/EGM Meetings
Announced on Meeting on
May 26, 2026 Jun 19, 2026
-
Aug 29, 2025 Sep 29, 2025
-
Aug 20, 2025 Sep 21, 2025
-
May 26, 2025 Jun 27, 2025
-
Dec 31, 2024 Feb 04, 2025
-

About Dishman Carbogen

Dishman Carbogen Amcis Ltd., incorporated in the year 2007, is a Small Cap company (having a market cap of Rs 2,825.86 Crore) operating in Pharmaceuticals sector.

Dishman Carbogen Amcis Ltd. key Products/Revenue Segments include Bulk Drugs & API, Other Operating Revenue, Raw Materials, Sale of services, Scrap and Duty Drawback for the year ending 31-Mar-2025.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 867.82 Crore, up 19.46 % from last quarter Total Income of Rs 726.46 Crore and up 19.81 % from last year same quarter Total Income of Rs 724.31 Crore. Company has reported net profit after tax of Rs 21.74 Crore in latest quarter.

The company’s top management includes Mr.Arpit J Vyas, Dr.Stephan Fritschi, Mrs.Deohooti J Vyas, Mr.Maitri K Mehta, Mr.Rajendra S Shah, Mr.Hemantkumar J Bhatt, Mr.Kulin N Shah, Dr.Margie S Parikh, Mr.Dhaval R Shah, Mr.Harshil Dalal, Mr.Paolo Armanino, Ms.Shrima G Dave. Company has V D Shukla & Co. as its auditors. As on 31-03-2026, the company has a total of 15.68 Crore shares outstanding.

Dishman Carbogen Share Price Today is Rs. 178.99. On previous day, the Dishman Carbogen Share Price (NSE) closed at Rs. 184.64, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 59.32% of the stake in Dishman Carbogen shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Dishman Carbogen stocks was 7.45% as compared to 7.66% in Dec 2025 with decrease of 0.21%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 1.62% as compared to 1.26% in Dec 2025 with increase of 0.36%. Out of the total DII holdings in Dishman Carbogen shares 1.06% was held by mutual funds. The rest including public held is 31.61%. Dishman Carbogen stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Dishman Carbogen Dividend: Ever since 2007, Dishman Carbogen dividends has been paid out around 1 times. As on 16 Jun, 2026, 09:02 AM IST, The overall dividend yield for Dishman Carbogen stands at 0.0%. The last dividend paid was on September 12, 2019 (Rs. 0.2). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 6.22.

Dishman Carbogen Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 867.82 Cr. of sales and 19.46% of quarterly net profit, there have been multiple ups and downs in the Dishman Carbogen stock prices in the past few weeks. For example, Dishman Carbogen stock price on 8th of June 2026 was around Rs. 184.37. Dishman Carbogen share price now stands at an average of Rs. 178.99. Judging by last week's performance, stock is in up trend.

Dishman Carbogen has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Dishman Carbogen share.

Historical Prices and Performance:
Dishman Carbogen, incorporated in 2007 is a Small Cap company (with a market cap of Rs. 2825.86) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Dishman Carbogen stock was 1.45%, 0.05%, -2.72%, -0.51% and 0.32% respectively.
The Dishman Carbogen share gave a 3 year return of 41.92% as compared to Nifty 50 which gave a return of 27.64%.
Dishman Carbogen announced 10.0% final dividend on September 12, 2019.

Key Metrics:
PE Ratio of Dishman Carbogen is 29.0
Prices/Sales Ratio of Dishman Carbogen is 0.7
Price/Book Ratio of Dishman Carbogen is 0.42

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Dishman Carbogen, major competitors and peers include Sequent Scientific, Sun Pharma Adv Res., Innova Captab and Orchid Pharma . As of Dec 2025, the dividend yield of Dishman Carbogen stands at 0.0% while Sequent Scientific, Sun Pharma Adv Res., Innova Captab and Orchid Pharma stand at 0.0%, 0.0%, 0.0% and 0.0% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 29.0 and 0.42 respectively.

Leadership of Dishman Carbogen :
Alan Fischer is Chief Technology Officer
Stephan Fritschi is Chief Executive Officer
Shrima G Dave is Co. Secretary & Compl. Officer
Harshil Dalal is Global Chief Financial Officer
Paolo Armanino is Chief Operating Officer
Arpit J Vyas is Managing Director
Deohooti J Vyas is Whole Time Director
Kulin N Shah is Director
Hemantkumar J Bhatt is Director
Margie S Parikh is Director
Maitri K Mehta is Independent Director
Rajendra S Shah is Independent Director
Dhaval R Shah is Additional Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

BSE SmallCap, BSE Healthcare, BSE AllCap, BSE Next 250 Microcap, Nifty Smallcap 500

Address

Dishman Corporate House,Iscon-Bopal Road,Ahmedabad, Gujarat - 380058

Contact

grievance@imdcal.com

http://www.imdcal.com

Executive Leadership

AJ

Arpit J Vyas

Managing Director

SF

Stephan Fritschi

Chief Executive Officer

DJ

Deohooti J Vyas

Whole Time Director

MK

Maitri K Mehta

Independent Director

Show More

Auditors

T R Chadha & Co. LLP

Haribhakti & Co. LLP

V D Shukla & Co.

FAQs about Dishman Carbogen share

1. What's Dishman Carbogen share price today and what are Dishman Carbogen share returns ?
Dishman Carbogen share price is Rs 178.99 as on 16 Jun, 2026, 09:02 AM IST. Dishman Carbogen share price is down by 0.70% based on previous share price of Rs 184.64. Dishman Carbogen share price trend:
- Last 3 Years: Dishman Carbogen Share price moved up by 42.28%
2. What is the PE & PB ratio of Dishman Carbogen?
The PE ratio of Dishman Carbogen stands at 29.0, while the PB ratio is 0.42.
3. What's the market capitalization of Dishman Carbogen?
Within the Pharmaceuticals sector, Dishman Carbogen stock has a market cap rank of 75. Dishman Carbogen has a market cap of Rs 2,825.86 Cr.
4. What is Dishman Carbogen's 52 week high / low?
Dishman Carbogen share price saw a 52 week high of Rs 321.95 and 52 week low of Rs 128.50.
5. What are the returns for Dishman Carbogen share?
Return Performance of Dishman Carbogen Shares:
- 1 Week: Dishman Carbogen share price moved down by 4.75%

Top Gainers

As on 03:59 PM | 15 Jun 2026

498.15

57.55 (13.07%)

Kalyan Jewellers Ind

383.00

38.25 (11.10%)

1,216.20

110.50 (10.00%)

Balkrishna Ind.

2,192.50

179.41 (8.92%)

Sundaram Finance

4,466.90

307.90 (7.41%)

Top Losers

As on 03:58 PM | 15 Jun 2026

81.55

-4.30 (-5.00%)

Aurobindo Pharma

1,408.30

-64.50 (-4.38%)

108.49

-4.11 (-3.66%)

Ola Electric Mobilit

44.12

-1.63 (-3.55%)

Aster DM Health

786.70

-28.25 (-3.47%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.